Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hau

Showing results (151-160 of 180) with videos related to

Pageof 18
Sort By:
Neuro-Oncology Practice|May 14, 2026
European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research projectEvangelia Razis, Thierry Gorlia, Matthias Preusser, et al.
Journal of Neuro-Oncology|July 21, 2019
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trialSied Kebir, Christina Schaub, Nina Junold, et al.
Clinical and Translational Radiation Oncology|May 20, 2024
Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)Sebastian H Maier, Stephan Schönecker, Vasiliki Anagnostatou, et al.
Neuro-Oncology|October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomideThomas Zeyen, Laura Böhm, Daniel Paech, et al.
The Lancet. Oncology|October 1, 2016
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyJaap C Reijneveld, Martin J B Taphoorn, Corneel Coens, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR TrialMichael Weller, Ghazaleh Tabatabai, Bärbel Kästner, et al.
Neuro-Oncology|November 10, 2017
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastomaNiklas Schäfer, Martin Proescholdt, Joachim P Steinbach, et al.
Trials|January 20, 2022
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trialThomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, et al.
Oncotarget|November 24, 2016
Prognostic relevance of miRNA-155 methylation in anaplastic gliomaMaximilian Georg Schliesser, Rainer Claus, Thomas Hielscher, et al.
Pageof 18

Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
Neuro-Oncology Practice|May 14, 2026
European neuro-oncology quality assessment (ENOQUA): A European organization for the research and treatment of cancer (EORTC) brain tumor group research projectEvangelia Razis, Thierry Gorlia, Matthias Preusser, et al.
Journal of Neuro-Oncology|July 21, 2019
Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trialSied Kebir, Christina Schaub, Nina Junold, et al.
Clinical and Translational Radiation Oncology|May 20, 2024
Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)Sebastian H Maier, Stephan Schönecker, Vasiliki Anagnostatou, et al.
Neuro-Oncology|October 1, 2024
Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with lomustine/temozolomideThomas Zeyen, Laura Böhm, Daniel Paech, et al.
The Lancet. Oncology|October 1, 2016
Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyJaap C Reijneveld, Martin J B Taphoorn, Corneel Coens, et al.
The Lancet. Oncology|March 10, 2009
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialRoger Stupp, Monika E Hegi, Warren P Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2015
MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR TrialMichael Weller, Ghazaleh Tabatabai, Bärbel Kästner, et al.
Neuro-Oncology|November 10, 2017
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastomaNiklas Schäfer, Martin Proescholdt, Joachim P Steinbach, et al.
Trials|January 20, 2022
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trialThomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, et al.
Oncotarget|November 24, 2016
Prognostic relevance of miRNA-155 methylation in anaplastic gliomaMaximilian Georg Schliesser, Rainer Claus, Thomas Hielscher, et al.
Pageof 18